Showing results (341-350 of 500) with videos related to
Sort By:
Pageof 50
Journal of Neuro-Oncology|August 26, 2009
Activation of PI3K/mTOR pathway occurs in most adult low-grade gliomas and predicts patient survivalSean M McBride, Daniel A Perez, Mei-Yin Polley, et al.Neuro-Oncology|December 10, 2023
Defining interventions and metrics to improve diversity in CNS clinical trial participation: A SNO and RANO effortJoshua A Budhu, Ugonma N Chukwueke, Sadhana Jackson, et al.Science Advances|March 12, 2025
Spatial 3D genome organization reveals intratumor heterogeneity in primary glioblastoma samplesQixuan Wang, Juan Wang, Radhika Mathur, et al.Neuro-Oncology|October 15, 2021
Improving the noninvasive classification of glioma genetic subtype with deep learning and diffusion-weighted imagingJulia Cluceru, Yannet Interian, Joanna J Phillips, et al.Neuro-Oncology|December 17, 2013
Heat-shock protein peptide complex-96 vaccination for recurrent glioblastoma: a phase II, single-arm trialOrin Bloch, Courtney A Crane, Yelena Fuks, et al.Cancer|August 1, 2017
Probing the phosphatidylinositol 3-kinase/mammalian target of rapamycin pathway in gliomas: A phase 2 study of everolimus for recurrent adult low-grade gliomasMichael Wahl, Susan M Chang, Joanna J Phillips, et al.Neurosurgical Focus|May 20, 2006
Safety of intraparenchymal convection-enhanced delivery of cintredekin besudotox in early-phase studiesSandeep Kunwar, Susan M Chang, Michael D Prados, et al.Neuro-Oncology|May 29, 2021
Heterogeneous delivery across the blood-brain barrier limits the efficacy of an EGFR-targeting antibody drug conjugate in glioblastomaBianca-Maria Marin, Kendra A Porath, Sonia Jain, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2007
Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study GroupSandeep Kunwar, Michael D Prados, Susan M Chang, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 7, 2007
Phase I study of temozolomide and irinotecan for recurrent malignant gliomas in patients receiving enzyme-inducing antiepileptic drugs: a north american brain tumor consortium studyMonica E Loghin, Michael D Prados, Patrick Wen, et al.Pageof 50